Cancer–testis antigen expression in triple-negative breast cancer
Authors:
- 7 July 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (1) , 98-103
Abstract
Background: Cancer–testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer. Patients and methods: A total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry. Results: A significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors. Conclusions: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer.Keywords
This publication has 37 references indexed in Scilit:
- CT-X antigen expression in human breast cancerProceedings of the National Academy of Sciences, 2009
- Genome-wide analysis of cancer/testis gene expressionProceedings of the National Academy of Sciences, 2008
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivityBreast Cancer Research and Treatment, 2008
- Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study GroupJournal of Clinical Oncology, 2008
- Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingProceedings of the National Academy of Sciences, 2008
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences, 2007
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-primingProceedings of the National Academy of Sciences, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsProceedings of the National Academy of Sciences, 2006
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003